A Short Review on Anti-diabetics for Uncontrolled Type 2 Diabetes Mellitus

Hussain Ahmad 1, Md. Abu Nayeem Chowdhury 2

Abstract

Introduction: This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade. Materials and Methods: This review is based on a search of Medline, the Cochrane Database of Systemic Reviews, and citation lists of relevant publications. Subject heading and key words used include type 2 diabetes mellitus, prevalence, current diagnosis, and current treatment. Only articles in English were included. Materials & Methods: Screening and diagnosis is still based on World Health Organization (WHO) and American Diabetes Association (ADA) criteria which include both clinical and laboratory parameters. No cure has yet been found for the disease; however, treatment modalities include lifestyle modifications, treatment of obesity, oral hypoglycemic agents, and insulin sensitizers is still the recommended first line medication. Other effective medications include non-sulfonylurea secretagogues, thiazolidinediones, alpha glucosidase inhibitors, and insulin. Recent research into the pathophysiology of type 2 DM has led to the introduction of new medications like glucagon-like peptide 1 analogoues: dipeptidyl peptidase-IV inhibitors, inhibitors of the sodium-glucose cotransporter 2 and 11ß-hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, metabolic inhibitors of hepatic glucose output and quick-release bromocriptine. Discussion: : Screening and diagnosis is still based on World Health Organization (WHO) and American Diabetes Association (ADA) criteria which include both clinical and laboratory parameters. No cure has yet been found for the disease; however, treatment modalities include lifestyle modifications, treatment of obesity, oral hypoglycemic agents, and insulin sensitizers is still the recommended first line medication. Other effective medications include non-sulfonylurea secretagogues, thiazolidinediones, alpha glucosidase inhibitors, and insulin. Recent research into the pathophysiology of type 2 DM has led to the introduction of new medications like glucagon-like peptide 1 analogoues: dipeptidyl peptidase-IV inhibitors, inhibitors of the sodium-glucose cotransporter 2 and 11ß-hydroxysteroid dehydrogenase 1, insulin-releasing glucokinase activators and pancreatic-G-protein-coupled fatty-acid-receptor agonists, glucagon-receptor antagonists, metabolic inhibitors of hepatic glucose output and quick-release bromocriptine. Conclusion: Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized depending on the characteristics of each patient.

Keywords: Type 2 diabetes mellitus, Diagnosis, Management, Newer drugs.

Number of Figures: 03; Number of References: 35; Number of Correspondences: 02

1. Corresponding Author:
   Dr. Hussain Ahmad
   Assistant Professor
   Department of Pharmacology & Therapeutics
   Sylhet Women’s Medical College
   Email: dr.hussainjmc@gmail.com
   H/P: 01716725485

2. Prof. Dr. Md. Abu Nayeem Chowdhury
   Professor
   Department of Pharmacology & Therapeutics
   Sylhet Women’s Medical College

Introduction

Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. The chronic hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure of different organs, especially the eyes, kidneys, nerves, heart, and blood vessels 1.

For decades, the diagnosis of diabetes was based on plasma glucose criteria, either the fasting plasma glucose (FPG) or the 2-hr value in the 75-gm oral glucose tolerance test (OGTT)2. Recently, an International Expert Committee recommended that HbA1c (threshold ≤6.5%) as a third option to diagnose diabetes mellitus (International Expert Committee, 2009) and ADA include this criteria in 2010 3.

Epidemiology of Diabetes Mellitus:

Diabetes mellitus (DM) has growing worldwide at an alarming rate. The highest increase is projected to be found in the urban population in developing countries. The International Diabetes Federation (IDF) most recently estimates that, 8.3% of adults - 382 million people around the world have diabetes in 2013, and the number of people with diabetes is set to rise beyond 592 million less than 25 years.Yet,175 million (46%) of cases currently undiagnosed, a vast amount of people with diabetes are progressing towards complications. Around 32 million people die in each year are attributable to complication of diabetes. A further 316 million people with impaired glucose tolerance are at high risk from the disease-an alarming number that is set to reach 471 million by 2035 4.

It is clear that diabetes is an ever growing endemic with no end. Centers for Disease Control and Prevention (CDC) reported that nearly 26 million Americans have diabetes. Diabetes affects 8.3% of Americans of
all ages, 11.3% of adults aged 20 years and older, and 25% of persons age 65 and older. In 2010 about 215,000 people younger than 20 years had diabetes (type 1 or type 2) in the United States 5. WHO termed diabetes as an emerging epidemic, is the 7th leading cause of death in the USA. WHO reported that approximately 560 million people worldwide will have diabetes by 2030. According to this report, Bangladesh has 8.4 million (10% of adult population) with diabetes in 2013 and the number is expected to increase to a staggering 11.1 million by 20306. Bangladesh is among the top 10 countries in number suffering by type-2 diabetes. The other countries suffering by diabetes are India, China, USA, Indonesia, Japan, Russia, Brazil, Italy and Pakistan. The prevalence of IGT in Bangladesh is 8.5% of adult population, which will rise to 8.8% by 2025 7. Increasing age and higher BMI were significant risk factors following both IGT and OGTT.

**Types of Diabetes mellitus:** Diabetes mellitus is classified on the basis of etiology and clinical presentation into four types: type-1 diabetes, type-2 diabetes, gestational diabetes, and other specific types. Type-1 diabetes results from β-cell destruction, usually leading to absolute insulin deficiency. Type-2 diabetes results from a progressive insulin secretory defect on the background of insulin resistance. Gestational diabetes mellitus (GDM) is diabetes diagnosed during pregnancy that is not clearly overt diabetes. Other specific types of diabetes due to other cause, e.g., genetic defects in β-cell function, genetic defects in insulin action, disease of the exocrine pancreas (such as cystic fibrosis), and drug or chemical-induced such as in the treatment of HIV/AIDS or after organ transplantation) 8.

**Aetiology:** The cause of type 2 diabetes mellitus appears to involve complex interactions between environmental and genetic factors. The disease may develop when a diabetogenic lifestyle (i.e., excessive caloric intake, inadequate caloric expenditure, obesity) is superimposed on a susceptible genotype. The body mass index (BMI) increases the risk for diabetes varies with different racial groups. For example, persons of Asian ancestry are at increased risk for diabetes at lower levels of overweight as compared with persons of European ancestry 9. Hypertension and pre-hypertension are associated with increased risk of developing diabetes in whites than in African Americans 10. In addition, low birth weight may predispose some individuals to develop type 2 diabetes mellitus 11.

About 90% of patients of type-2 diabetes mellitus are obese. However, a large, population-based prospective study has shown that an energy-dense diet may be a risk factor for the development of diabetes independent of baseline obesity 12.

**Major risk factors:** The major risk factors for type 2 diabetes mellitus are the following: (i) Age greater than 45 years; (ii) Weight greater than 120% of desirable body weight; (iii) Family history of type 2 diabetes in a first-degree relative (e.g., parent or sibling); (iv) Previous impaired glucose tolerance (IGT) or impaired fasting glucose (IFG); (v) Hypertension (BP>140/90 mm Hg) or dyslipidemia (HDL cholesterol level <40 mg/dL or triglyceride level >150 mg/dL); (vi) History of gestational diabetes mellitus or of delivering a baby with a birth weight of over 9 lb; (vii) Polycystic ovarian syndrome (which results in insulin resistance); (viii) Genetic influences; and (ix) Depression 13.

**Pathophysiology:** Diabetic Mellitus is a metabolic disorder characterized by inability to regulate blood glucose. Several pathogenic processes are involved in the development of diabetes. These range from autoimmune destruction of the β-cells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action. The basis of the abnormalities in carbohydrate, fat, and protein metabolism in diabetes is deficient action of insulin on target tissues. Deficient insulin action results from inadequate insulin secretion or diminished tissue responses to insulin at one or more points in the complex pathways of hormone action. Impairment of insulin secretion and defects in insulin action frequently coexist in the same patient, and it is often unclear which abnormality, if either alone, is the primary cause of the hyperglycemia 2. A simplified scheme for the pathophysiology of abnormal glucose metabolism in type 2 diabetes mellitus is depicted in the figure no. 1.

**Presentation of DM:** Symptoms of marked hyperglycemia including polyuria, polyphagia, polydipsia, weight loss, blurred vision and generalized weakness are typical features of diabetes mellitus. Impairment of growth and susceptibility to certain infections may also accompany chronic hyperglycemia. A short list includes non-healing wound infection, infertility or repeated pregnancy loss, undue fatigability, purities vulvae etc 3. Acute, life-threatening consequences of uncontrolled diabetes are hyperglycemia with ketoacidosis or the non-ketotic hyperosmolar syndrome 3.

**Diagnosis:** The American Diabetes Association current criteria for the diagnosis of diabetes 3:
- An HbA1c level of 6.5% or higher; the test should be performed in a laboratory using immunoassay (by Boronate affinity assay) method that is certified by the National Glycohemoglobin Standardization Program (NGSP) and

---

**Figure-1:** Simplified scheme for the pathophysiology of type 2 diabetes mellitus 14.
Diabetes Control and Complications Trial (DCCT), or
• A fasting blood glucose (FBG) level of 126 mg/dL (7.0 mmol/L) or higher; fasting is defined as no caloric diet intake for at least 8 hours before giving blood, and estimated by ‘Glucose Oxidase’ method, or
• A two-hour post prandial blood glucose level of 200 mg/dL (11.1 mmol/L) or higher during an oral glucose tolerance test (OGTT).

The test should be performed as described by the World Health Organization, using a glucose load containing the equivalent of 75 gm glucose dissolved in 250ml of water drinking 5-10 min, or
• A random blood glucose of 200 mg/dL (11.1 mmol/l) or higher in a patient with classical symptoms of hyperglycemia (i.e., polyuria, polydipsia, polyphagia, weight loss) or hyperglycemic crisis.


If hyperglycemia is absent, then HbA1c, FBG, and OGTT results should be confirmed by repeat testing. The ADA recommends repeating the same test for confirmation, since there will be a greater likelihood of concurrence. However, the diagnosis of diabetes is also confirmed if the results of 2 different tests are above the diagnostic thresholds 2.

If a patient has 2 different tests and the results are discordant, the test that has a result above the diagnostic threshold should be repeated. A second abnormal result on this test will confirm the diagnosis 15.

In asymptomatic patients whose random blood glucose level suggests diabetes (>140 mg/dL), an FBG or HbA1c level should be measured. FBG level of 100-125 mg/dL is considered an impaired fasting glucose (IFG), and FBG level of less than 100 mg/dL is considered as a normal fasting glucose.

Complications of diabetes: Patients with long-standing diabetes are at risk of developing a variety of complications. 25% of people with type-2 diabetes have evidence of diabetic complications at the time of initial diagnosis. Acute complications of DM are diabetic ketoacidosis, hypoglycaemia, hyperosmolar non ketotic coma and lactic acidosis 16.

Chronic complications of DM are:
1. Micro-vascular: (a) Retinopathy (b) Nephropathy (c) Peripheral neuropathy.
2. Macro-vascular: (a) Cerebrovascular disease (b) cardiovascular disease (c) peripheral vascular disease.
3. Others: Gastrointestinal: (a) gastroparesis, diarrhoea (b) genito urinary- uropathy, sexual dysfunction. (c) Dermopathy (d) Infections (e) Cataract glaucoma (f) Periodontal disease 17.

Among the various complications, diabetic neuropathy is relatively early and common complication affecting approximately 30% of diabetic patients 18.

Management of Diabetes mellitus: The goals of management of patients with diabetes mellitus are to eliminate symptoms and to prevent the development of complications. Reduction of microvascular complication (i.e., eye and kidney disease) is accomplished through control of hyperglycemia and blood pressure; and that of macrovascular complication (i.e., cardiovascular, cerebrovascular & peripheral vascular disease), through control of dyslipidemia and hypertension, smoking cessation, aspirin therapy, metabolic and neurologic risk reduction and control of hyperglycemia 13. An ideal plan of management includes (i) appropriate goal setting, (ii) dietary and exercise modifications, (iii) medications, (iv) appropriate self-monitoring of blood glucose (SMBG) level, (v) regular monitoring for complications, and (vi) Laboratory assessment 13.

Ideally, blood glucose should be maintained at near-normal levels (preprandial levels of glucose (72-126) mg/dl and hemoglobin A1c [HbA1c] levels <7%). However, focus on glucose alone does not provide adequate treatment for patients with diabetes mellitus. Treatment involves multiple goals (i.e, glycemic status, lipid profile and blood pressure) 13. There is no cure of diabetes, rather the traditional treatment as diet control, regular exercise & drug therapy - would control glucose metabolism.

A lot of drugs are using to control diabetes. It becomes difficult to control type 2 diabetes nowadays although we have many drugs. This article reviews the treatments available for patients with T2DM, with an emphasis on agents introduced within the last decade.

Materials and Methods

This review is based on a search of Medline, the Cochrane Database of Systemic Reviews, and citation lists of relevant publications. Subject heading and key words used include type 2 diabetes mellitus, prevalence, current diagnosis, and current treatment. Only articles in English were included.

Pharmacological Therapy: Early initiation of pharmacological therapy is associated with improved glycemic control and reduced long-term complications in type 2 diabetes. Drug classes used for the treatment of type 2 diabetes include the following:
1) Oral anti-diabetic agent
2) Injectable anti-diabetic agent – Insulin

Oral anti-diabetic agent may be classified as:

a) Insulin Secretagogues:
   i. Sulfonylurea-
      • 1st generation – Tolbutamide, Chlorpropamide.
      • 2nd generation – Glibenclamide, Glipizide, Gliclazide, Glimepiride.
   ii. Nonsulphonylureas-
      • Meglitinide analogue – Repaglinide.
      • D-phenyl-alanine derivatives – Nateglinide
   b) Insulin sensitizers
      i. Biguanide – Metformin
      ii. Thiazolidinediones – Pioglitzazone, Rosiglitazone
c) Alpha-glucosidase inhibitors – Acarbose

d) Incretin based therapy:

i. Dipeptidyl peptidase IV inhibitors - Sitagliptin, Vildaglaptin, Saxagliptin and Linagliptin

ii. Glucagon like peptide-1(GLP-1) analogues – exenatide, (Subcutenious rout), Liraglutide 7,19

e) Na-glucose co-transporter-2 inhibitor in renal tubules – Dapagliflozine.

Injectable agents (Insulin) may be classified as:

a) Conventional: Short acting (regular insulin), intermediate acting (NPH, lente), and long acting (ultralente)

b) Analogues: rapid acting analogues (aspart, lispro, glulisine), long acting analogues (glargine, detemir, degludec)

c) Pre-mixed insulin (conventional and analogues) 20.

Mechanism of action of different Oral anti-diabetic drugs:
Mechanism of different oral anti-diabetic agent describes briefly in the Figure no. 2. Insulin secretogogues – like sulfonylureas, meglitinides, and phenylalanine derivatives – stimulate more Insulin secretion; and Biguanides acts against Insulin resistance and enhance Insulin activity. They both thus prevent blood glucose level to be raised in type 2 diabetic patient. Thiazolidinediones enhance peripheral glucose uptake, mostly by the skeletal muscles. And alpha-glucosidase inhibitors prevent well absorption of carbohydrate from the intestine.

**Figure-2: Mechanism of action of different OADs** 21

**Doses and duration of Gliclazide for treatment of diabetes mellitus:**
Daily total dose of Gliclazide is 40-320 mg, dosing schedule is 1 to 2 times/day and duration of action is 12-24 hours 20.

**Indication:** Type 2 diabetes mellitus patient 20.

**Advantage:** Potent; reduce pre- and post-prandial BG (Blood glucose) 7.

**Disadvantage:** Hypoglycemia, Gastro-intestinal upset, Weight gain 20.

**Limitation:** Impaired hepatic and renal function 20.

**Pharmacokinetics of metformin:** Only route of administration is oral; well absorbed from G.I.T. Maximum duration of action: 24 hours; 1½ is 1.5 - 3 hours hour. It is not bound to plasma protein; not metabolized in liver; and excreted unchanged by the kidneys 20.

**Mechanism of action of metformin**: Metformin acts by reduction of hepatic glucose production, enhancement of insulin sensitivity and increasing glucose uptake by peripheral tissues 20.

**Doses and duration of Metformin for treatment of diabetes mellitus:** Total daily dose of metformin is 500-2550 mg, dosing schedule is 2-3 times/day and duration of action is 8-12 hours 20.

**Indication of Metformin**: Patient with Type 2 diabetes mellitus, gestational diabetes mellitus, pregnant patient with existing type2 DM, Polycystic ovarian syndrome 20.

**Advantage:** Improves insulin sensitivity, weight reduction, reduce pre- (mostly) and post-prandial blood glucose, favorable effects on lipid profile 7.

**Disadvantage:** G.I.T. upsets include Anorexia, Nausea, Vomiting, Diarrhoea, lactic acidosis 20.

**Limitation:** Impaired renal and hepatic function 20.

**Insulin in type 2 DM:** Due to progressive nature of type 2 DM, many individuals require insulin to optimize glycemic control over time as oral hypoglycemic agents fail to achieve targets. This failure termed as primary and secondary OHA failure 7. The incidence of secondary drug failure, as published in literature is 0.3% to 30% 22. So, alternative treatment option is needed for controlling blood glucose level. Recently introduced incretin based therapies has been opened new hope for glycemic control in DM treatment 23.

**Incretin and incretin based therapies for Diabetes treatment:** Incretins are local hormones that are released after ingestion of a meal and augment the secretion of insulin. These hormones are Gastric inhibitory polypeptide (GIP) and Glucagon-like peptide-1 (GLP-1) 24. Current research suggests that GLP-1 (glucagon-like peptide-1) is the most important. Because GLP-1 stimulates insulin secretion only under hyperglycemic conditions, there is minimal risk of hypoglycemia; GLP-1 is also associated with increased satiety, possibly because it reduces the rate of gastric emptying. People with type 2 diabetes have reduced circulating levels of GLP-1 but retain their ability to respond to this hormone. Thus, it is possible to improve glycemic control through administration of exogenous GLP-1 25. Unfortunately, under normal physiological conditions, GLP-1 and GIP are rapidly degraded by the enzyme system DPP-IV and therefore are not themselves viable as pharmacological agents 23. Agents that act as incretin mimetic, such as exenatide and liraglutide, and DPP-4 inhibitors, such as sitagliptin, vildagliptin, linagliptin and saxagliptin, improve glycated hemoglobin levels either as monotherapy or in combination with other agents. Importantly, these agents either lead to weight loss or are weight neutral and are associated with a low risk of hypoglycemia—properties that further contribute to their clinical utility. Although DPP-IV inhibition has been...
Doses and duration of Sitagliptin for treatment of diabetes mellitus: Recommended dose is 100 mg once daily, duration of action is 24 hours.

Indication of Sitagliptin: Sitagliptin used as monotherapy and as add-on therapy to either of two other types of oral diabetes medications, metformin or thiazolidinediones in type 2 DM patient.

Advantage: Weight loss, decreased pre and post prandial blood glucose, may associated with increase beta cell mass and survival.

Disadvantage: Upper respiratory tract infection (Nasopharyngitis), may cause pancreatitis, may cause GIT upset.

Pharmacology of Insulin glargine: Insulin glargine is a long-acting analog of human insulin that is produced following two alterations of human insulin. Two arginine residues are added to the C terminus of the B chain, and an asparagine molecule in position 21 on the A chain is replaced with glycine.

Insulin glargine is a clear solution with a pH of 4.0, which stabilizes the insulin hexamer. When injected into the neutral pH of the subcutaneous space, aggregations occurs, resulting in prolonged, but predictable, absorption from the injection site. Owing to insulin glargine’s acidic pH, it cannot be mixed with short-acting insulin preparations (i.e., regular insulin, aspart, or lispro) that are formulated at a neutral pH.

In clinical studies glargine has a sustained peakless absorption profile, and provides a better once-daily 24-hour insulin coverage than NPH insulin. Evidence from clinical trials also suggests that glargine has a lower risk of hypoglycemia, particularly overnight compared to NPH insulin. Glargine may be administered at any time during the day with equivalent efficacy and does not accumulate after several injections. Glargine has been shown in clinical studies to normalize fasting (post absorptive) glucose levels following once-daily administration in patients with type 2 diabetes.
Sometimes, splitting the dose of glargine may be needed in very insulin-sensitive type 1 diabetes patients to achieve fasting (basal) glucose levels in the target range and avoid hypoglycemia. Unlike traditional insulin preparations that are absorbed more rapidly from the abdomen than from the arm or leg, the site of administration does not influence the time-action profile of glargine. Similarly, exercise does not influence glargine’s unique absorption kinetics, even when the insulin is injected into a working limb.

Glargine binds with a slightly greater affinity to IGF-1 receptors as compared with human insulin. However, this slightly increased binding is still approximately two log scales lower than that of IGF-1. Controversy currently exists whether glargine insulin is associated with an increased chance of malignancy or an acceleration of underlying malignancy, but most feel that the available evidence is circumstantial and not sufficiently convincing to change prescribing patterns.

**Discussion of safety and efficacy of using the agents using multi drug approach in uncontrolled type 2 diabetic patients:** Aschner et al., (2012) conducted a comparative, parallel, randomized, open label trial of 6 months. In this 6 month study 732 patients with uncontrolled type2 diabetes patients treated with metformin were enrolled. Then insulin glargine (n=250) was given in one group subcutaneously at a dose of 0.2 unit/kg body weight; while in another group, sitagliptin (n=265) was given at a dose of 100 mg once daily as add on therapy. At the end of 6 month period they concluded that insulin glargine was better in the achievement of optimum glycemic control in type 2 diabetes patients inadequately controlled by metformin.

Arecchavalet et al., (2011) conducted a study to evaluate the efficacy and safety of adding sitagliptin 100 mg daily or glimepiride (starting dose 1 mg/day up to 6 mg/day) to the treatment regimen of patients with type 2 diabetes mellitus with inadequate glycemic control on metformin monotherapy. They concluded that the addition of sitagliptin or glimepiride led to similar improvement of glycemic control after 30 weeks. Sitagliptin at a dose of 100 mg once daily was added in addition to existing therapy in one group and insulin glargine as add on therapy in another group. At the end of the treatment period of 24 weeks they observed that sitagliptin significantly reduced HbA1c and FBG in comparable to insulin glargine. Moreover, insulin glargine caused weight gain (0.7kg) whereas sitagliptin caused small weight loss (0.3 kg). The efficacy and safety of sitagliptin as monotherapy were evaluated in Chinese, Indian and Korean patients with type 2 DM inadequately controlled by diet and exercise. In this randomized, placebo-controlled, double-blind, 18 week trial 530 patients received sitagliptin 100 mg once daily or placebo. In this study, sitagliptin monotherapy for 18 weeks significantly improved glycemic control and was well tolerated in patients with type-2 diabetes from China, India and Korea.

**Conclusion**

Lifestyle modifications and metformin are the cornerstone of the initial management of T2DM, there is an increasing array of second and third-line pharmacological agents for this condition. At present there are different families of oral and injectable drugs, available for the treatment of T2DM. These include sulfonylureas, meglitinides, insulin, TZD and alpha-glucosidase inhibitors, and recently with the addition of RA-GLP1 receptor agonists, iDPP4 and iSGLT2. Moreover, insulin analogues that better simulate endogenous insulin secretion have been developed. Metformin remains the first choice of treatment for most patients. Other alternative or second-line treatment options should be individualized taking into consideration patient characteristics as degree of hyperglycaemia, presence of co-morbidities, and patient preference and ability to access treatments; and properties of the treatment such effectiveness and durability of lowering blood glucose, risk of hypoglycaemia, effectiveness in reducing diabetes complications, effect on body weight, side effects and contraindications. Although it does not appear that in the
near future cure diabetes, novel safety and effective agents that will improve the quality of life of T2DM patients, are developing.

Conflict of Interests: None.

Acknowledgement
The authors thanks to Dr. K. M. Hafizur Rahman, Lecturer, Department of Pharmacology & Therapeutics, Sylhet Women’s Medical College, for his technical support in preparing this article.

References
https://doi.org/10.2337/dc14-S005
https://doi.org/10.2337/dc14-S014
PMid:24357209
https://doi.org/10.2337/dc14-S081
PMid:24357215
https://doi.org/10.1016/S0140-6736(03)15268-3
https://doi.org/10.2337/dc10-1786
PMid:21346180 PMCID:PMC3064044
https://doi.org/10.2337/dc12-0168
PMid:22923665 PMCID:PMC3507591
https://doi.org/10.2337/dc08-1085
PMid:18689693 PMCid:PMC2571060
https://doi.org/10.2147/DHPS.S6270
https://doi.org/10.2337/diacare.13.6.696
PMid:2162756
https://doi.org/10.2337/dc09-1499
PMid:20103558 PMCid:PMC2809297

https://doi.org/10.2337/clinad.26.2.53

https://doi.org/10.1111/j.1463-1326.2010.01212.x
PMid:20590741

https://doi.org/10.2147/vhrm.2007.3.2.203
PMid:17580730 PMCid:PMC1994027


https://doi.org/10.1016/S0140-6736(12)60439-5

https://doi.org/10.1111/j.1463-1326.2010.01334.x
PMid:21199268

https://doi.org/10.2337/dc06-0706
PMid:17130197

https://doi.org/10.1111/j.1463-1326.2006.00704.x
PMid:17300595

https://doi.org/10.1089/dia.2010.0120
PMid:21175268

https://doi.org/10.1016/j.diabres.2008.10.009
PMid:19097665

https://doi.org/10.1111/j.1463-1326.2006.00704.x
PMid:17300595

https://doi.org/10.1089/dia.2010.0120
PMid:21175268

https://doi.org/10.1016/j.diabres.2008.10.009
PMid:19097665